Stockscreener 앱 받기
7.29
4.08%
-0.31
시간 외 거래:
7.20
-0.09
-1.23%
전일 마감가:
$7.60
열려 있는:
$7.49
하루 거래량:
51,451
Relative Volume:
1.49
시가총액:
$535.50M
수익:
$31.80M
순이익/손실:
$-58.49M
주가수익비율:
-1.0574
EPS:
-6.894
순현금흐름:
$-17.58M
1주 성능:
+1.84%
1개월 성능:
-8.65%
6개월 성능:
-33.24%
1년 성능:
-34.37%
1일 변동 폭
$7.2025
$7.7799
1주일 범위
$6.68
$8.0899
52주 변동 폭
$6.4652
$16.52
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
7.29 | 558.27M | 31.80M | -58.49M | -17.58M | -6.894 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Big Picture: Why is Xilio Therapeutics Inc stock going downWeekly Risk Report & Proven Capital Preservation Methods - baoquankhu1.vn
Analysis Recap: Whats the outlook for JB Hunt Transport Services Incs sector2026 Selloffs & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Xilio Therapeutics to present data on masked cancer therapy at AACR - Investing.com
Xilio Therapeutics to Present Poster on XTX601 at AACR Annual Meeting 2026 - Quiver Quantitative
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program ... - Bluefield Daily Telegraph
Xilio Therapeutics to Present New Preclinical Data for its - GlobeNewswire
Xilio Therapeutics (NASDAQ:XLO) Shares Down 4.8%What's Next? - MarketBeat
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - Bitget
Inflation Data: Whats the fair value of Xilio Therapeutics Inc stock2026 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Trading Halt: Halted at 7:50:00 p.m. ETTrading Halt: Halt News PendingXilio Therapeutics (NASDAQ:XLO) - Benzinga
Xilio Therapeutics implements 1-for-14 reverse stock split By Investing.com - Investing.com India
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split - Sahm
Published on: 2026-03-13 07:54:21 - baoquankhu1.vn
Xilio Therapeutics implements 1-for-14 reverse stock split - Investing.com South Africa
Xilio Therapeutics (Nasdaq: XLO) enacts 1-for-14 reverse stock split - Stock Titan
Xilio Therapeutics Advances Masked Immuno-Oncology Therapies with Robust Pipeline, Strategic Partnerships, and Strong Financials (2026 Update) - Minichart
Xilio Therapeutics Updates Investor Presentation on I-O Strategy - TipRanks
Xilio Therapeutics posts investor presentation highlighting pipeline, $137.5M cash and upcoming INDs - TradingView
Cash runway to 2027: Xilio Therapeutics (NASDAQ: XLO) details I-O pipeline - Stock Titan
XLO SEC FilingsXilio Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Can Xilio Therapeutics Inc expand into new marketsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Institution Moves: How sustainable is Xilio Therapeutics Inc. stock dividend payout2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - Naître et grandir
Chipmakers Recap: Is Xilio Therapeutics Inc benefiting from innovation trendsJuly 2025 Trends & Smart Money Movement Tracker - baoquankhu1.vn
Xilio Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Press Release: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
Xilio Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
XLO PE Ratio & Valuation, Is XLO Overvalued - Intellectia AI
Is Xilio Therapeutics Inc. benefiting from innovation trendsPortfolio Performance Report & Free Technical Confirmation Trade Alerts - mfd.ru
Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split - The Globe and Mail
Xilio Therapeutics (NASDAQ: XLO) gains stockholder OK for reverse stock split range - Stock Titan
Entry Recap: Why is Xilio Therapeutics Inc stock going down2025 Top Gainers & Capital Efficient Trading Techniques - baoquankhu1.vn
Will Xilio Therapeutics Inc. stock reach Wall Street targetsWeekly Investment Report & Fast Gaining Stock Strategy Reports - mfd.ru
Form 4: GILEAD SCIENCES, INC. reports purchase transactions in XLO - Stock Titan
What is the long term forecast for Xilio Therapeutics Inc. stockEarnings Overview Report & High Yield Equity Trading Tips - mfd.ru
Xilio Therapeutics Prices Pre-Funded Warrant Offering Financing - The Globe and Mail
What is the Moat Score of Xilio Therapeutics Inc.July 2025 Opening Moves & Daily Volume Surge Trade Alerts - mfd.ru
Xilio Therapeutics Signs Underwriting Agreement With Leerink Partners - TradingView
Xilio Therapeutics (NASDAQ: XLO) raises ~$40M via 74.8M pre-funded warrants - Stock Titan
Gilead discloses 19.9% stake in Xilio Therapeutics (XLO) ownership filing - Stock Titan
Xilio Therapeutics Launches Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics Prices $40M Underwritten Offering - National Today
Xilio Therapeutics Prices Pre-Funded Warrant Offering - Intellectia AI
Xilio Therapeutics Announces Pricing of Underwritten Offering - Yahoo Finance
Xilio Therapeutics announces pricing of underwritten offering - marketscreener.com
Xilio Therapeutics Announces Pricing Of Underwritten Offering - TradingView
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):